Indoco Remedies Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
299.50 -4.80 (-1.58%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
299
Today’s High
305
52 Week Low
286.5
52 Week High
416.95
299.80 -4.50 (-1.48%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
298.5
Today’s High
305
52 Week Low
286.6
52 Week High
414
Key Metrics
- Market Cap (In Cr) 2804.2
- Beta 0.67
- Div. Yield (%) 0.49
- P/B 2.53
- TTM P/E 107.37
- Peg Ratio 48.99
- Sector P/E 31.15
- D/E 0.77
- Open Price 304
- Prev Close 304.3
Indoco Remedies Analysis
Price Analysis
-
1 Week-0.75%
-
3 Months-9.37%
-
6 Month-3.41%
-
YTD-23%
-
1 Year-12.32%
Risk Meter
- 25% Low risk
- 25% Moderate risk
- 25% Balanced Risk
- 25% High risk
- 25% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 0
- 0
- 1
- 1
- Buy
- 1
- 1
- 1
- 1
- Hold
- 2
- 2
- 1
- 1
- Sell
- 0
- 0
- 0
- 0
- Strong Sell
- 0
- 0
- 0
- 0
- Total
- 3
- 3
- 3
- 3
Indoco Remedies News
Indoco Remedies Q2 Results: Loss at ₹9.57Cr, Revenue Decreased by 10.19% YoY
1 min read . 25 Oct 2024Indoco Remedies, KRBL & others hit 52 week low today ;Check the full list here?
3 min read . 30 May 2024Uno Minda, Indian Bank & others hit 52 week high today ; Do you own any?
3 min read . 30 May 2024Indoco Remedies Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 1817.29
- Selling/ General/ Admin Expenses Total
- 361.93
- Depreciation/ Amortization
- 91.87
- Other Operating Expenses Total
- 554.7
- Total Operating Expense
- 1653.32
- Operating Income
- 163.97
- Net Income Before Taxes
- 135.8
- Net Income
- 98.47
- Diluted Normalized EPS
- 9.63
- Period
- 2024
- Total Assets
- 2144.73
- Total Liabilities
- 1034.83
- Total Equity
- 1109.9
- Tangible Book Valueper Share Common Eq
- 99.99
- Period
- 2024
- Cashfrom Operating Activities
- 145.79
- Cashfrom Investing Activities
- -433.83
- Cashfrom Financing Activities
- 280.44
- Net Changein Cash
- -7.6
- Period
- 2023
- Total Revenue
- 1668.61
- Selling/ General/ Admin Expenses Total
- 670.86
- Depreciation/ Amortization
- 70.61
- Other Operating Expenses Total
- 39.3
- Total Operating Expense
- 1451.67
- Operating Income
- 216.94
- Net Income Before Taxes
- 192.79
- Net Income
- 142.25
- Diluted Normalized EPS
- 15.54
- Period
- 2023
- Total Assets
- 1658.2
- Total Liabilities
- 629.95
- Total Equity
- 1028.25
- Tangible Book Valueper Share Common Eq
- 98.1
- Period
- 2023
- Cashfrom Operating Activities
- 178.84
- Cashfrom Investing Activities
- -208.17
- Cashfrom Financing Activities
- 22.8
- Net Changein Cash
- -6.53
- Period
- 2022
- Total Revenue
- 1540.75
- Selling/ General/ Admin Expenses Total
- 582.36
- Depreciation/ Amortization
- 77.21
- Other Operating Expenses Total
- 33.5
- Total Operating Expense
- 1291.84
- Operating Income
- 248.92
- Net Income Before Taxes
- 236.57
- Net Income
- 154.8
- Diluted Normalized EPS
- 16.96
- Period
- 2022
- Total Assets
- 1486.09
- Total Liabilities
- 581.45
- Total Equity
- 904.64
- Tangible Book Valueper Share Common Eq
- 88.19
- Period
- 2022
- Cashfrom Operating Activities
- 173.83
- Cashfrom Investing Activities
- -121.41
- Cashfrom Financing Activities
- -44.37
- Net Changein Cash
- 8.05
- Period
- 2021
- Total Revenue
- 1241.53
- Selling/ General/ Admin Expenses Total
- 514.68
- Depreciation/ Amortization
- 73.13
- Other Operating Expenses Total
- 35.59
- Total Operating Expense
- 1090.12
- Operating Income
- 151.41
- Net Income Before Taxes
- 132
- Net Income
- 93.05
- Diluted Normalized EPS
- 10.12
- Period
- 2021
- Total Assets
- 1315.06
- Total Liabilities
- 546.07
- Total Equity
- 768.99
- Tangible Book Valueper Share Common Eq
- 74.27
- Period
- 2021
- Cashfrom Operating Activities
- 82.22
- Cashfrom Investing Activities
- -66.69
- Cashfrom Financing Activities
- -29.87
- Net Changein Cash
- -14.34
- Period
- 2020
- Total Revenue
- 1106.58
- Selling/ General/ Admin Expenses Total
- 530.34
- Depreciation/ Amortization
- 67.95
- Other Operating Expenses Total
- 23.01
- Total Operating Expense
- 1053.94
- Operating Income
- 52.64
- Net Income Before Taxes
- 28.57
- Net Income
- 24.12
- Diluted Normalized EPS
- 2.9
- Period
- 2020
- Total Assets
- 1271.6
- Total Liabilities
- 592.03
- Total Equity
- 679.57
- Tangible Book Valueper Share Common Eq
- 63.82
- Period
- 2020
- Cashfrom Operating Activities
- 122.85
- Cashfrom Investing Activities
- -55.93
- Cashfrom Financing Activities
- -63.95
- Net Changein Cash
- 2.97
- Period
- 2019
- Total Revenue
- 968.45
- Selling/ General/ Admin Expenses Total
- 454.54
- Depreciation/ Amortization
- 71.57
- Other Operating Expenses Total
- 23.72
- Total Operating Expense
- 963.16
- Operating Income
- 5.29
- Net Income Before Taxes
- -9.31
- Net Income
- -2.9
- Diluted Normalized EPS
- -0.28
- Period
- 2019
- Total Assets
- 1258.05
- Total Liabilities
- 597.43
- Total Equity
- 660.62
- Tangible Book Valueper Share Common Eq
- 61.36
- Period
- 2019
- Cashfrom Operating Activities
- 132.11
- Cashfrom Investing Activities
- -103.76
- Cashfrom Financing Activities
- -16.14
- Net Changein Cash
- 12.22
- Period
- 2018
- Total Revenue
- 1045.3
- Selling/ General/ Admin Expenses Total
- 444.58
- Depreciation/ Amortization
- 67.71
- Other Operating Expenses Total
- 21.18
- Total Operating Expense
- 977.91
- Operating Income
- 67.38
- Net Income Before Taxes
- 48.4
- Net Income
- 41.16
- Diluted Normalized EPS
- 4.32
- Period
- 2018
- Total Assets
- 1237.93
- Total Liabilities
- 562.95
- Total Equity
- 674.98
- Tangible Book Valueper Share Common Eq
- 61.58
- Period
- 2018
- Cashfrom Operating Activities
- 122.72
- Cashfrom Investing Activities
- -135.43
- Cashfrom Financing Activities
- -38.77
- Net Changein Cash
- -51.48
- Period
- 2024-09-30
- Total Revenue
- 432.66
- Selling/ General/ Admin Expenses Total
- 92.88
- Depreciation/ Amortization
- 28.82
- Other Operating Expenses Total
- 147.46
- Total Operating Expense
- 421.23
- Operating Income
- 11.43
- Net Income Before Taxes
- -4.84
- Net Income
- -9.57
- Diluted Normalized EPS
- -1.09
- Period
- 2024-09-30
- Total Assets
- 2389.83
- Total Liabilities
- 1300.3
- Total Equity
- 1089.53
- Tangible Book Valueper Share Common Eq
- 97.99
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 111.9
- Cashfrom Investing Activities
- -226.92
- Cashfrom Financing Activities
- 118.34
- Net Changein Cash
- 3.32
- Period
- 2024-06-30
- Total Revenue
- 431.49
- Selling/ General/ Admin Expenses Total
- 97.26
- Depreciation/ Amortization
- 27.52
- Other Operating Expenses Total
- 120.28
- Total Operating Expense
- 411.24
- Operating Income
- 20.25
- Net Income Before Taxes
- 6.97
- Net Income
- 2.63
- Diluted Normalized EPS
- 0.2
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 449.64
- Selling/ General/ Admin Expenses Total
- 88.3
- Depreciation/ Amortization
- 26.23
- Other Operating Expenses Total
- 148.25
- Total Operating Expense
- 407.27
- Operating Income
- 42.37
- Net Income Before Taxes
- 32.98
- Net Income
- 22.7
- Diluted Normalized EPS
- 1
- Period
- 2024-03-31
- Total Assets
- 2144.73
- Total Liabilities
- 1034.83
- Total Equity
- 1109.9
- Tangible Book Valueper Share Common Eq
- 99.99
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 145.79
- Cashfrom Investing Activities
- -433.83
- Cashfrom Financing Activities
- 280.44
- Net Changein Cash
- -7.6
- Period
- 2023-12-31
- Total Revenue
- 459.42
- Selling/ General/ Admin Expenses Total
- 89.97
- Depreciation/ Amortization
- 24.35
- Other Operating Expenses Total
- 140.06
- Total Operating Expense
- 429.07
- Operating Income
- 30.35
- Net Income Before Taxes
- 22.63
- Net Income
- 16.3
- Diluted Normalized EPS
- 2.27
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 481.73
- Selling/ General/ Admin Expenses Total
- 92.12
- Depreciation/ Amortization
- 21.41
- Other Operating Expenses Total
- 145.16
- Total Operating Expense
- 431.77
- Operating Income
- 49.96
- Net Income Before Taxes
- 46.28
- Net Income
- 35.08
- Diluted Normalized EPS
- 3.82
- Period
- 2023-09-30
- Total Assets
- 1938.04
- Total Liabilities
- 869.7
- Total Equity
- 1068.34
- Tangible Book Valueper Share Common Eq
- 99.71
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 46.6
- Cashfrom Investing Activities
- -122.4
- Cashfrom Financing Activities
- 125.89
- Net Changein Cash
- 50.09
- Period
- 2023-06-30
- Total Revenue
- 426.5
- Selling/ General/ Admin Expenses Total
- 91.54
- Depreciation/ Amortization
- 19.88
- Other Operating Expenses Total
- 121.23
- Total Operating Expense
- 385.21
- Operating Income
- 41.29
- Net Income Before Taxes
- 33.91
- Net Income
- 24.39
- Diluted Normalized EPS
- 2.62
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 428.15
- Selling/ General/ Admin Expenses Total
- 76.69
- Depreciation/ Amortization
- 17.69
- Other Operating Expenses Total
- 131.18
- Total Operating Expense
- 381.09
- Operating Income
- 47.06
- Net Income Before Taxes
- 38.91
- Net Income
- 25.8
- Diluted Normalized EPS
- 2.8
- Period
- 2023-03-31
- Total Assets
- 1658.2
- Total Liabilities
- 629.95
- Total Equity
- 1028.25
- Tangible Book Valueper Share Common Eq
- 98.1
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 178.84
- Cashfrom Investing Activities
- -208.17
- Cashfrom Financing Activities
- 22.8
- Net Changein Cash
- -6.53
- Period
- 2022-12-31
- Total Revenue
- 399.2
- Selling/ General/ Admin Expenses Total
- 82.13
- Depreciation/ Amortization
- 17.17
- Other Operating Expenses Total
- 104.85
- Total Operating Expense
- 354.33
- Operating Income
- 44.87
- Net Income Before Taxes
- 38.22
- Net Income
- 28.14
- Diluted Normalized EPS
- 3.05
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Indoco Remedies Technical
Moving Average
SMA
- 5 Day308.08
- 10 Day309.49
- 20 Day311.36
- 50 Day338.97
- 100 Day338.13
- 300 Day337.72
Indoco Remedies Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- RPG Life Sciences
- 2027.1
- -16.25
- -0.8
- 2976.7
- 1290.3
- 3352.62
- Alembic
- 123.8
- -1.4
- -1.12
- 169
- 78.2
- 3179.18
- Indoco Remedies
- 299.5
- -4.8
- -1.58
- 416.95
- 286.5
- 2761.39
- Suven Life Sciences
- 118
- -2.8
- -2.32
- 169
- 75.95
- 2573.27
- Novartis India
- 1024.35
- 1.45
- 0.14
- 1248
- 685
- 2529.2
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- RPG Life Sciences
- 38.61
- 9.03
- 22.53
- 11.99
- Alembic
- 11.98
- 1.47
- 13.55
- 71.82
- Indoco Remedies
- 31.02
- 2.53
- 12.02
- 6.93
- Suven Life Sciences
- -
- 9.77
- -52.35
- -787.61
- Novartis India
- 31.14
- 3.39
- 6.07
- 11.47
Indoco Remedies Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 24-Oct-24
- Quarterly Results
- 23-Jul-24
- Quarterly Results
- 16-May-24
- Audited Results & Final Dividend
- 23-Jan-24
- Quarterly Results
- 19-Oct-23
- Quarterly Results
- 25-Jul-23
- Quarterly Results
- 23-May-23
- Audited Results & Final Dividend
- 24-Jan-23
- Quarterly Results
- 10-Nov-22
- Quarterly Results
- 09-Aug-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 26-Sept-24
- 30-Aug-24
- AGM
- 26-Sept-23
- 01-Sept-23
- AGM
- 27-Jun-23
- 26-May-23
- POM
- 23-Sept-21
- 02-Jul-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 16-May-24
- -
- 19-Sept-24
- 1.5
- 23-May-23
- -
- 18-Sept-23
- 2.25
- 17-May-22
- -
- 14-Sept-22
- 1.5
- 18-May-22
- -
- 14-Sept-22
- 0.75
- 25-May-21
- -
- 17-Sept-21
- 1.5